Status:
COMPLETED
Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Ipsen
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to analyse clinical data of well-differentiated grade 3 digestive neuroendocrine tumors. These rare tumors may have a different disease evolution, response to chemotherapy...
Detailed Description
Digestive neuroendocrine tumors are rare tumors and cell differentiation is a major prognostic marker of neuroendocrine tumors. The 2010 WHO Classification defined three groups of tumor according to ...
Eligibility Criteria
Inclusion
- Well-differentiated grade 3 neuroendocrine digestive tumors
- Patient of 18 years old and more
Exclusion
- Patient opposed to data collection as part of the study
- Digestive neuroendocrine tumors Grade 1-2
- Grade 3 poorly differentiated digestive neuroendocrine tumors
- Malignant disease diagnosed in the last 5 years (except basal cell of the skin and in situ cervical carcinoma)
- Other non-digestive neuroendocrine tumors
- Mixed neuroendocrine non neuroendocrine neoplasm
Key Trial Info
Start Date :
July 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 25 2023
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT04365023
Start Date
July 2 2020
End Date
May 25 2023
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterology and digestive oncology unit - Cochin hospital
Paris, France, 75014